Satellos Bioscience (NASDAQ:MSLE) Downgraded to “Strong Sell” Rating by Wall Street Zen

Satellos Bioscience (NASDAQ:MSLE) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a note issued to investors on Saturday.

MSLE has been the topic of several other research reports. Cantor Fitzgerald started coverage on shares of Satellos Bioscience in a report on Wednesday. They issued an “overweight” rating on the stock. Weiss Ratings began coverage on Satellos Bioscience in a report on Wednesday, February 11th. They set a “sell (d-)” rating on the stock. Finally, Zacks Research upgraded Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Satellos Bioscience Trading Down 6.5%

Shares of NASDAQ MSLE opened at $8.00 on Friday. Satellos Bioscience has a 52-week low of $4.53 and a 52-week high of $13.39. The stock has a market cap of $123.68 million, a PE ratio of -6.66 and a beta of 1.10.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.